Pediococcus acidilactici preparation as well as preparation method and application thereof

Through the application of the A62 preparation of Lactate Tablets A62, the obesity and metabolic disorders caused by feeding livestock and poultry with high fat and high cholesterol were solved, which significantly reduced the serum cholesterol and liver steatosis of mice and laying hens, and improved the antioxidant ability and Laying hen production performance improves egg quality.

CN119020205APending Publication Date: 2024-11-26CHINA AGRI UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411090519.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-09
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

Feeding of livestock and poultry with high fat and high cholesterol causes obesity and metabolic disorders in livestock and poultry and humans. The existing technology is difficult to effectively reduce the cholesterol content in livestock and poultry products, affecting the economy and health of the animal husbandry industry.

Method used

Using Pediococcus acidilactici A62 preparation, it was prepared by mixing fermentation broth with carrier and drying and crushing at low temperature. It was used to feed mice and laying hens, significantly reducing serum cholesterol and liver steatosis, improving intestinal flora and anti-aging Oxidation capacity.

Benefits of technology

Effectively reduce the weight and serum cholesterol levels of obese mice and laying hens, improve antioxidant ability, improve laying hen production performance and egg quality, and reduce egg cholesterol content.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure FT_2
    Figure FT_2
  • Figure FT_3
    Figure FT_3
Patent Text Reader

Abstract

The invention discloses a pediococcus acidilactici preparation as well as a preparation method and application thereof. The invention provides pediococcus acidilactici A62 and a pediococcus acidilactici preparation prepared by using the strain, wherein the pediococcus acidilactici A62 is separated from chyme of healthy poultry, can resist artificial gastrointestinal fluid, can reduce serum cholesterol content, and can relieve mouse obesity caused by eating high-fat daily ration by improving intestinal flora structure. The invention further provides application of the pediococcus acidilactici in improving the production performance of laying hens, improving the oxidation resistance of the laying hens, improving the quality of eggs and reducing cholesterol of the eggs.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the field of biotechnology, in particular to a Pediococcus acidilactici preparation and a preparation method and application thereof. Background Art

[0002] In humans and animals, high-calorie diets and poor fat metabolism will cause excess energy to be stored in the body in the form of fat, causing obesity and high cholesterol in the body. High-calorie, high-fat, and high-cholesterol foods need to be reduced in the daily diet to prevent the occurrence of obesity. With people's increasing attention to health issues, people are paying more and more attention to the ingredients of food, and low-fat and low-cholesterol meat, eggs, and milk are particularly favored by consumers. However, with the increase in people's demand for livestock and poultry products such as meat, eggs, and milk, some businesses often choose high-fat, high-calorie feeds to feed livestock and poultry in order to accelerate fattening in a short period of time, shorten the time to market, reduce costs, and improve economic benefits. The high-fat components in the diet can cause abnormal lipid metabolism in animals, induce chronic metabolic diseases in livestock and poultry, and cause economic losses. Therefore, it is very important to find ways to alleviate diseases such as lipid metabolism disorders in obese animals caused by high-fat diets.

[0003] Eggs are cheap and have high nutritional value. As a food that people eat frequently, they are questioned by consumers because of their high cholesterol content, which affects the production and consumption of eggs. Studies have shown that the cholesterol in an egg is as high as 230 mg. The daily cholesterol intake of a healthy human body should be less than 300 mg, and for people with metabolic diseases, the cholesterol intake should be even lower. Therefore, it is urgent to reduce the cholesterol in food, and the research and development of low-cholesterol eggs has become one of the important tasks of animal husbandry researchers.

[0004] Lactic acid bacteria (LAB) refers to the general term for non-spore, Gram-positive bacteria that can ferment sugars and whose main product is lactic acid. Most lactic acid bacteria have important physiological functions and are essential to the human body. They are the main microorganisms in the human digestive tract and the main microbial group in the intestines of animals. Due to their positive physiological functions for humans and animals, lactic acid bacteria are widely used as probiotics and are also considered to be the most representative intestinal probiotics. Lactic acid bacteria colonize and proliferate in the intestines, participate in the metabolism of sugars and fats in the body, block the production of fat, promote the decomposition of deposited fat in the body, and play a role in weight loss.

[0005] Therefore, screening lactic acid bacteria with lipid-lowering and cholesterol-lowering potential, exploring their lipid-lowering and cholesterol-lowering mechanisms, and applying them to the production of low-cholesterol livestock and poultry products have important theoretical value and practical significance. Summary of the invention

[0006] The purpose of the present invention is to provide a Pediococcus acidilactici preparation and a preparation method and application thereof.

[0007] In order to achieve the purpose of the present invention, in a first aspect, the present invention provides a Pediococcus acidilactici preparation, wherein the Pediococcus acidilactici preparation is a preparation of Pediococcus acidilactici ( Pediococcus acidilactici ) The fermentation liquid of A62 and the carrier are mixed in a weight ratio of (0.5-0.8):1, dried at low temperature, and crushed to obtain the dry powder of Pediococcus acidilactici.

[0008] The Pediococcus acidilactici A62 of the present invention has a deposit number of CGMCC NO. 28922, and the strain has been disclosed in CN117987328A.

[0009] Furthermore, the carrier is selected from one or more of bran, rice husk powder, waste flour, corn cob powder and corn gluten powder.

[0010] In a second aspect, the present invention provides a method for preparing the Pediococcus acidilactici preparation, comprising the following steps: (1) inoculating the lactic acid Pediococcus into an MRS culture medium, placing the culture medium in a constant temperature incubator at 37° C. for 12 h, and then inoculating the culture medium into a fermentation tank at an inoculum amount of 5% to 10% (volume ratio), culturing for 18 to 24 h, and obtaining a fermentation liquid (liquid preparation) of the lactic acid Pediococcus; The fermentation medium is: molasses 5%, soybean meal 2%, ammonium sulfate 0.1%, crystalline sodium acetate 0.1%, dipotassium hydrogen phosphate 0.5%, anhydrous magnesium sulfate 0.02%, manganese sulfate 0.005%, Tween-80 0.1% v / v, pH 6.5 ± 0.2; except for Tween-80, all are in mass percentage; (2) The lactic acid Pediococcus fermentation liquid and the carrier are mixed evenly in a weight ratio of (0.5-0.8):1, dried at 40-50°C, and crushed to obtain the product.

[0011] In a third aspect, the present invention provides the use of Pediococcus acidilactici A62 or its bacterial agent or the Pediococcus acidilactici preparation in the preparation of a drug for reducing the body weight of obese animals and obese people and lowering serum cholesterol.

[0012] The animals include mice, livestock and poultry, etc.

[0013] In a fourth aspect, the present invention provides use of Pediococcus acidilactici A62 or its bacterial agent or the Pediococcus acidilactici preparation in improving the antioxidant capacity and immune function of mice.

[0014] In a fifth aspect, the present invention provides use of Pediococcus acidilactici A62 or its bacterial agent or the Pediococcus acidilactici preparation in improving the intestinal flora of mice.

[0015] In a sixth aspect, the present invention provides use of Pediococcus acidilactici A62 or its bacterial agent or the Pediococcus acidilactici preparation in improving the production performance of livestock and poultry.

[0016] In a seventh aspect, the present invention provides use of Pediococcus acidilactici A62 or its bacterial agent or the Pediococcus acidilactici preparation in improving the antioxidant capacity of livestock and poultry.

[0017] In an eighth aspect, the present invention provides use of Pediococcus acidilactici A62 or its bacterial agent or the Pediococcus acidilactici preparation in improving the quality of poultry eggs (including reducing poultry egg cholesterol).

[0018] Compared with the prior art, the present invention has at least the following advantages: The present invention provides a lactic acid Pediococcus A62 isolated from healthy animals and capable of efficiently degrading cholesterol, and a lactic acid Pediococcus preparation prepared using the strain. The lactic acid Pediococcus and the lactic acid Pediococcus preparation can be used to alleviate the obesity symptoms of mice induced by a high-fat diet. The lactic acid Pediococcus can significantly slow down the weight gain of mice fed a high-fat diet, significantly reduce serum total cholesterol (TC) and liver total cholesterol, alleviate liver fatty degeneration of obese mice, reduce oxidative stress of obese mice, and improve their antioxidant properties. The lactic acid Pediococcus and the lactic acid Pediococcus preparation of the present invention can also effectively improve the production performance of laying hens, improve the antioxidant capacity of laying hens, improve egg quality, and reduce egg cholesterol. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] Figure 1 It is the survival rate of the candidate strain in artificial gastric juice in the preferred embodiment of the present invention.

[0020] Figure 2 It is the survival rate of the candidate strain in the artificial intestinal fluid in the preferred embodiment of the present invention.

[0021] Figure 3 It is the bile salt tolerance of the candidate strain in the preferred embodiment of the present invention.

[0022] Figure 4 It is the acid tolerance of the candidate strain in the preferred embodiment of the present invention.

[0023] Figure 5 The growth curve and acid production curve of strain A62 in the preferred embodiment of the present invention are shown.

[0024] Figure 6 The colony morphology and bacterial morphology of strain A62 in the preferred embodiment of the present invention.

[0025] Figure 7 This is the phylogenetic tree of strain A62 in a preferred embodiment of the present invention.

[0026] Figure 8 This is the alleviation of fatty degeneration of mouse liver by Pediococcus acidilactici A62 in a preferred embodiment of the present invention.

[0027] Fig. 9This is a Venn diagram of the number of OTUs in the mouse cecal flora in a preferred embodiment of the present invention.

[0028] Fig.10 This is the PCoA analysis of mouse cecal flora in a preferred embodiment of the present invention.

[0029] Fig.11 This is the NMDS analysis of the mouse cecal flora in a preferred embodiment of the present invention.

[0030] Fig.12 The composition of mouse cecal microorganisms at the phylum level in a preferred embodiment of the present invention.

[0031] Fig.13 This is the composition of mouse cecal microorganisms at the genus level in a preferred embodiment of the present invention.

[0032] Fig.14 This is the evolutionary branch diagram of the mouse cecal flora in a preferred embodiment of the present invention.

[0033] Fig.15 This is the comparative analysis result of LEfSe in the preferred embodiment of the present invention.

[0034] Fig.16 This is the effect of Pediococcus acidilactici on egg cholesterol in a preferred embodiment of the present invention. DETAILED DESCRIPTION

[0035] The present invention provides a kind of Pediococcus acidilactici with lipid-lowering and cholesterol-lowering properties ( Pediococcus acidilactici ) and its application in weight loss in high-fat diet-induced obese mice, improving the production performance of laying hens and reducing the cholesterol content of eggs.

[0036] The present invention adopts the following technical solution: The present invention provides a strain of Pediococcus acidilactici A62, which is isolated from chicken cecal chyme. After multiple probiotic performance tests and in vitro and in vivo tests, it is confirmed that the strain has antibacterial function and has lipid-lowering and cholesterol-lowering effects. The strain was deposited in the General Microbiological Center of the China Microbiological Culture Collection Administration (CGMCC) on November 9, 2023, and was classified and named Pediococcus acidilactici ( Pediococcus acidilactici ), deposit number is CGMCC NO. 28922. This strain has been disclosed in CN117987328A.

[0037] The microbiological characteristics of Pediococcus acidilactici CGMCC NO. 28922 are as follows: (1) The colony morphology of the strain is round protrusions, milky white, moist, and has neat edges; (2) Microscopic morphology: Gram-positive, no spores, no flagella, flake-like, Gram-positive staining; (3) Other characteristics: The bacteria is facultative anaerobic and can grow well in MRS liquid culture medium. The pH can be reduced to about 3.9 after fermentation.

[0038] The present invention also provides a bacterial agent containing the Pediococcus acidilactici.

[0039] The present invention also provides a Pediococcus acidilactide preparation prepared by using the Pediococcus acidilactide. The Pediococcus acidilactide preparation is a liquid or a dry powder. The specific preparation process is as follows: (1) The lactic acid Pediococcus is inoculated into an MRS medium, cultured at a constant temperature of 37° C. for 12 h, and then inoculated into a fermentation tank at an inoculum amount of 5% to 10%, and cultured at 37° C. for 18 to 24 h to obtain a lactic acid Pediococcus fermentation liquid. The fermentation medium of lactic acid Pediococcus is: 5% molasses, 2% soybean meal, 0.1% ammonium sulfate, 0.1% crystalline sodium acetate, 0.5% dipotassium hydrogen phosphate, 0.02% anhydrous magnesium sulfate, 0.005% manganese sulfate and 0.1% Tween-80 (v / v), pH 6.5 ± 0.2.

[0040] (2) The lactic acid Pediococcus fermentation liquid and the carrier are uniformly mixed in a weight ratio of (0.5-0.8):1, dried at low temperature, and crushed to obtain lactic acid Pediococcus dry powder. The carrier can be one or more of bran, rice husk powder, rice flour, corn cob powder and corn gluten powder.

[0041] The present invention also provides the use of the Pediococcus acidilactici or its bacterial agent or the Pediococcus acidilactici preparation in the preparation of biological products for reducing the body weight of obese mice, reducing serum cholesterol and improving antioxidant capacity.

[0042] The lactic acid Pediococcus and the lactic acid Pediococcus preparation are further used to reduce the body weight of obese mice, reduce serum cholesterol, and improve antioxidant capacity.

[0043] The invention feeds a high-fat diet to induce an obesity model of C57BL / 6 mice, and administers Pediococcus acidibiotic to the mice, and detects the influence of Pediococcus acidibiotic on lipid metabolism of obese mice. The results show that Pediococcus acidibiotic A62 can reduce the body weight of obese mice induced by a high-fat diet, can reduce the TC and LDL-C contents in serum and the TC content in the liver, and at the same time, Pediococcus acidibiotic A62 can increase the T-AOC and CAT contents in the mice, and reduce the MDA content, and alleviate the fatty degeneration of the liver. Therefore, Pediococcus acidibiotic A62 can reduce the harm of obesity to mice by reducing cholesterol in the plasma and liver of obese mice and improving their antioxidant capacity.

[0044] The present invention also provides application of the Pediococcus acidilactici or the Pediococcus acidilactici preparation in improving the production performance of laying hens.

[0045] The present invention also provides application of the Pediococcus acidilactici or the Pediococcus acidilactici preparation in improving the antioxidant capacity of laying hens.

[0046] The present invention also provides use of the Pediococcus acidilactici or the Pediococcus acidilactici preparation in improving egg quality.

[0047] The present invention also provides use of the Pediococcus acidilactici or the Pediococcus acidilactici preparation in reducing cholesterol in eggs.

[0048] The following examples are used to illustrate the present invention, but are not intended to limit the scope of the present invention. Unless otherwise specified, the technical means used in the examples are conventional means well known to those skilled in the art, and the raw materials used are all commercially available products.

[0049] The percentage sign "%" involved in the present invention, unless otherwise specified, refers to mass percentage; however, the percentage of a solution, unless otherwise specified, refers to the number of grams of solute contained in 100 mL of solution.

[0050] Example 1 Isolation, screening and identification of lactic acid bacteria with high cholesterol-lowering properties in vitro

[0051] 1. Isolation of lactic acid bacteria and screening of efficient cholesterol-degrading strains

[0052] Sample collection: healthy pigs, chicken cecal chyme, kimchi and other fermented foods.

[0053] MRS medium: peptone 1.0%, yeast extract powder 0.5%, beef powder 1%, glucose 2%, dipotassium hydrogen phosphate 0.2%, anhydrous sodium acetate 0.5%, triammonium citrate 0.2%, magnesium sulfate heptahydrate 0.0575%, manganese sulfate monohydrate 0.014%, Tween-80 0.1% v / v, agar powder. Sterilization conditions: sterilize at 121℃ for 20min, set aside. For screening medium, add 0.01% bromocresol purple to MRS medium.

[0054] Cholesterol solution: 1 g of fat-soluble cholesterol was added into anhydrous ethanol and stirred to dissolve. After fully dissolved, the volume was adjusted to 50 mL with anhydrous ethanol to prepare a 20 mg / mL cholesterol solution.

[0055] MRS-CHOL medium: Add 5% (v / v) cholesterol solution to MRS medium and shake while adding the cholesterol solution to form stable cholesterol micelles.

[0056] Single colonies were isolated from each sample, and single colonies that met the culture characteristics and colony morphology of lactic acid bacteria were selected. The fermentation broth of each strain was inoculated into MRS-CHOL medium at a ratio of 2%, and cultured in a shaker at 37°C and 100 r / min for 24 h. The cholesterol content was determined after culture. Three strains with a cholesterol degradation rate of more than 50%, including lactic acid bacteria A11, A62, and A93, were selected for stress resistance screening.

[0057] 2. Screening of stress resistance of highly efficient cholesterol-lowering lactic acid bacteria

[0058] The strains with cholesterol degradation rate > 50% were inoculated into MRS culture medium and cultured in a 37°C constant temperature incubator for 12 h. The OD 600 , the bacterial solution was used for subsequent screening.

[0059] 2.1 Survival rate in simulated gastric and intestinal fluid

[0060] After activation, each strain was inoculated into a mixture of artificial gastric juice and MRS medium at a ratio of 1:1 at 10% (v / v). After culturing for 6 h, the OD 600 , calculate the survival rate.

[0061] After activation, each strain was inoculated into a mixture of artificial intestinal fluid and MRS culture medium at a ratio of 1:1 at 10% (v / v). After culturing for 6 h, the OD 600 , calculate the survival rate.

[0062] For probiotics to enter the body and exert their effects, they must first ensure that sufficient numbers of them survive as they pass through the digestive tract. Figure 1 As shown in the figure, the survival rates of the three strains in gastric juice decreased over time. The survival rate of strain A93 in gastric juice was higher than that of other strains, and the survival rate of A62 was slightly lower. At 4 hours, its survival rate was still over 93%. The three strains also showed a high survival rate in simulated intestinal fluid. At 4 hours, the survival rates of the three strains were all over 95%, and at 6 hours, the survival rates were over 89% ( Figure 2 ).

[0063] 2.2 Bile salt tolerance of strains

[0064] Each strain was inoculated into MRS medium containing 0.1%, 03%, and 0.5% ox bile salts, respectively. After culturing at 37°C for 24 h, samples were taken, plate counts were made, and the survival rate of the strains was calculated.

[0065] The three lactic acid bacteria grew well at a bile salt concentration of 0.1%, with survival rates of more than 80%. Among them, A62 had the best bile salt tolerance, with a survival rate of more than 67% at a bile salt concentration of 0.5%. Figure 3 ).

[0066] 2.3 Temperature tolerance of strains

[0067] The three strains showed a certain degree of tolerance when treated at 65℃ for 1-5 min, among which A62 had the strongest tolerance, with a survival rate of 62% after treatment at 65℃ for 5 min ( Figure 4 ).

[0068] Among the candidate strains, strain A62 showed stronger cholesterol degradation ability and stress resistance, so A62 was selected as the strain for further research.

[0069] 3. Determination of basic growth performance of target strains

[0070] The A62 strain was inoculated into MRS culture medium and cultured continuously in a 37°C constant temperature incubator for 36 h. Samples were taken every 2 h to measure the OD 600 and pH value, and draw the growth curve and pH change curve.

[0071] The growth characteristics and acid production characteristics of strain A62 were determined ( Figure 5 ), at the 18th hour, the growth of strain A62 entered the plateau phase, and its acid production also reached the plateau phase, with the final pH of the fermentation being 3.9-4.0.

[0072] 4. Identification of strains

[0073] A62 strain colonies ( Figure 6 ) is a milky white, moist, round protrusion with neat edges; the bacteria are flaky in shape and Gram-positive.

[0074] The 16S rRNA gene of strain A62 was identified and the sequencing results were compared with the NCBI database by BLAST. Pediococcus acidilactici The 16S rRNA gene homology of 14-S2 (Pediococcus acidilactici) is 99% ( Figure 7 ), the strain was identified as Pediococcus acidilactici.

[0075] Example 2 Effects of Pediococcus acidilactici A62 on high-fat diet-induced obese mice

[0076] 1. Materials and Methods

[0077] 40 4-week-old SPF C57 / BL 6J male mice weighing about 15g were randomly divided into 4 groups (n=10). The normal control group (NC) mice were fed with ordinary feed and gavaged with 0.2 mL of sterile saline every day. The model control group (MC) mice were fed with high-fat feed and gavaged with 0.2 mL of sterile saline every day. The positive control group (PC) mice were fed with high-fat feed and gavaged with 20 mg / kg orlistat every day according to body weight, with a volume of 0.2 mL. The experimental group (T) mice were fed with high-fat feed and gavaged with 0.2 mL (10 8 CFU / mouse) fermentation broth of Pediococcus acidilactici A62. The experimental period was 10 weeks, mice were allowed to drink water freely, and gavage was performed at 5:00 pm every day.

[0078] After the experiment, blood was collected from the eyeballs, serum was separated, and frozen at -80°C for the determination of blood biochemical indicators. The mice were killed by cervical dislocation, and the fat of the mice was collected and weighed. After the liver of the mice was weighed, a small piece of liver was cut and quickly frozen at -80°C for the determination of liver biochemical indicators and antioxidant capacity.

[0079] One-way ANOVA in IBM SPSS Statistics 26 was used to analyze the mean values ​​of the data. If the variance analysis was significant, the least significant difference (LSD) method was used to compare the differences between the means. P <0.05 indicated that the difference reached the significant level.

[0080] 2. Results

[0081] 2.1 Pediococcus acidilactici reduces body weight in diet-induced obese mice

[0082] As shown in Table 1, the body weight of the model control group mice fed with a high-fat diet was significantly higher than that of the normal control group ( P <0.05), indicating that the high-fat diet-induced obesity model was successful, and the intervention of Pediococcus acidilactici could significantly reduce the body weight of high-fat diet-induced obese mice ( P <0.05), and the body weight gain of mice in the Pediococcus acidilactici group was significantly lower than that of the positive control group fed with orlistat ( P <0.05), and even lower than the normal control group fed with ordinary diet.

[0083] 2.2 Pediococcus acidilactici reduces total cholesterol in diet-induced obese mice

[0084] The serum total cholesterol content of the model control group fed with a high-fat diet was significantly higher than that of the normal control group, indicating that a high-fat diet can cause a significant increase in the serum total cholesterol content of mice, while the serum total cholesterol content of the lactic acid Pediococcus test group was lower than that of the model control group (P <0.05), close to the serum cholesterol content of mice in the normal control group.

[0085] 2.3 Pediococcus acidilactici improves the antioxidant capacity of mouse liver

[0086] The T-AOC level of mice in the Pediococcus acidilactici gavage group was higher than that in the normal control group and the model control group ( P <0.05), meanwhile, the MDA level in the liver of mice in the P. acidilactici gavage group decreased ( P <0.05), the results showed that the antioxidant capacity of high-fat diet-induced obese mice was improved through the intervention of Pediococcus acidilactici.

[0087] Table 1 Effects of Pediococcus acidilactici on various parameters of mice

[0088] Note: TC: total cholesterol, TG: triglyceride, LDL: low-density lipoprotein cholesterol, HDL: high-density lipoprotein cholesterol, T-AOC: total antioxidant capacity, MDA: malondialdehyde, CAT: catalase; a、b、c :Different superscript letters in the same row indicate that the difference reaches the significant level, ( P <0.05).

[0089] 2.4 Pediococcus acidilactici alleviates hepatic steatosis in high-fat diet-induced obese mice

[0090] Feeding a high-fat diet caused fatty degeneration in the liver of mice, with a large number of lipid droplets appearing in the liver. Although gavage with oselita reduced the number of lipid droplets in the liver to a certain extent, the lipid droplets also became significantly larger. In contrast, gavage with Pediococcus acidilactici significantly reduced the number of lipid droplets in the liver and the size of lipid droplets ( Figure 8 ), therefore, the intervention of Pediococcus acidilactici alleviated the fatty degeneration of the liver in high-fat diet-induced obese mice.

[0091] Example 3 Effect of Pediococcus acidilactici A62 on the intestinal flora of obese mice induced by a high-fat diet

[0092] 1. Materials and Methods

[0093] 40 4-week-old SPF C57 / BL 6J male mice weighing about 15g were randomly divided into 4 groups (n=10). The normal control group (NC) mice were fed with ordinary feed and gavaged with 0.2 mL of sterile saline every day. The model control group (MC) mice were fed with high-fat feed and gavaged with 0.2 mL of sterile saline every day. The positive control group (PC) mice were fed with high-fat feed and gavaged with 20 mg / kg orlistat every day according to body weight, with a volume of 0.2 mL. The experimental group (T) mice were fed with high-fat feed and gavaged with 0.2 mL (10 8 CFU / mouse) fermentation broth of Pediococcus acidilactici A62. The experimental period was 10 weeks, mice were allowed to drink water freely, and gavage was performed at 5:00 pm every day.

[0094] After the experiment, the contents of the mouse cecum were collected in a test tube and quickly frozen at -80°C. After sampling, it was sent to Shanghai Meiji Biopharmaceutical Technology Co., Ltd. for sequencing.

[0095] The variable regions (V3 and V4) of the 16S rRNA gene sequences of mouse cecal microorganisms were sequenced, and biodiversity analysis was performed based on the sequencing results. The sequences finally obtained were classified into operational taxonomic units (OTUs), and the Alpha diversity level and Beta diversity level of each sample were evaluated based on the distribution of OTUs in different samples, and the intestinal flora microorganisms were analyzed at the phylum level and genus level.

[0096] 2. Results

[0097] Fig. 9 The OTU Venn diagram of the cecal bacterial samples of four groups of mice. The normal control group (NC), model control group (MC), positive control group (PC), and Pediococcus acidilactici group (T) each had a total of 1060, 461, 447, and 447 OTU sets. The four groups had a total of 219 OTU sets, 34 OTUs shared between the normal control group and the model control group, and 14 and 26 OTUs shared between the model control group and the positive control and experimental groups, respectively.

[0098] According to Table 2, the Courage index of all groups was higher than 0.99, indicating that the samples of all groups could represent the entire intestinal flora. The Shannon index, Chao1 index and ACE index of the model control group were significantly reduced, indicating that the high-fat diet reduced the diversity of the intestinal flora of mice. The various indexes of the lactic acid Pediococcus group were lower than those of the normal control group, and the differences in Chao1 index and ACE index reached a significant level (P<0.05).

[0099] Table 2 Results of Alpha diversity analysis of intestinal flora

[0100] PCoA analysis of Beta diversity shows that the higher the similarity between different samples, the more concentrated the points. In the NMDS analysis graph, the closer the sample points in different groups are, the more similar the species composition of the two samples is. The stress value in the NMDS graph is an indicator to test the quality of the NMDS analysis results. If the stress value is <0.2, the graph is considered to have a certain meaning. If the stress value is <0.1, it is generally considered to be good. If the stress value is <0.05, it is considered to be very representative. Fig.10 , Fig.11 It can be seen that the points of each group are concentrated, indicating that the parallelism between the groups is very high, and the difference between the normal control group and the other three groups reached a significant level, indicating that the high-fat diet changed the diversity of the intestinal flora of mice, and the gap between the lactic acid bacteria group and the normal control group was smaller.

[0101] At door level ( Fig.12 ), the intestinal contents of the four groups were mainly composed of Firmicutes, followed by Bacteroidetes, Actinobacteria and Verrucobacteria. Compared with the normal control group, the Firmicutes in the other three groups increased and the Bacteroidetes decreased. At the genus level, the top ten genera were Coriobacteriaceae_UCG-002, unclassified_f_Lachnospiraceae, norank_f_Muribaculaceae, Akkermansia, Faecalibaculum, Dubosiella, Blautia, Eubacterium_fissicatena_group, Lachnospiraceae_NK4A136_group, and Faecalitalea. At the genus level ( Fig.13 ), feeding a high-fat diet led to a significant increase in the content of Corlobacterlaceae-UGG-002, unclassified-f-Lachnosplraceae, Akkermansla, and Eubacterlum-flsslcatena-group in the cecum of mice, and a significant decrease in the content of norank-f-Murlbaculaceae and Lachnosplraceze-NK4A136-group.

[0102] The samples were compared at all taxonomic levels by comparing the differences in species of intestinal flora in different groups. The relative abundance of different types was analyzed using LEfSe. In the four groups, the types were considered as markers for distinguishing intestinal microorganisms in different treatments. Fig.14 , Fig.15 It can be seen that the abundance of g-Akkermansia, f-Ruminococcaceae, and g-Lachnoclostridium in the model control group was higher, while the abundance of Ruminococcus and Lactobacillus in the lactic acid Pediococcus group was the highest, indicating that the target strain can increase the abundance of beneficial bacteria in the intestine, and the enrichment of these beneficial bacteria is beneficial to weight loss in mice fed a high-fat diet.

[0103] Example 4 Effect of Pediococcus acidilactici on the production performance of laying hens

[0104] 1. Materials and Methods

[0105] In this example, 960 352-day-old Hy-Line brown laying hens were randomly divided into three groups: the first group was a blank control group (CON, fed with a basic diet), the second group was a low-dose Pediococcus acidilactici group (LPa, basic diet + 1×10 8 CFU / kg diet), the third group was a high-dose Pediococcus acidilactici group (HPa, basic diet + 1×10 9 CFU / kg diet), 4 replicates per group, 80 chickens per replicate. The duration was 6 weeks (1 week for pre-test and 5 weeks for formal period), during which the feed intake, egg number and egg weight were recorded and the feed-egg ratio was calculated.

[0106] 2. Results

[0107] Adding low doses of Pediococcus acidilactici to feed significantly increased the egg production rate of laying hens ( P <0.05), during the formal period, the egg production rates of the low-dose lactic acid Pediococcus group and the high-dose lactic acid Pediococcus group were 3.30% and 2.45% higher than those of the control group, respectively. After adding lactic acid Pediococcus, there was no significant change in the feed intake, egg weight and feed-egg ratio of laying hens, but the feed-egg ratio tended to decrease (Table 3). The above results show that the addition of lactic acid Pediococcus to feed can significantly improve the production performance of laying hens.

[0108] Table 3 Effects of Pediococcus acidilactici on production performance of laying hens

[0109] Note: Data in the same column with different letters on their shoulders indicate significant differences ( P <0.05).

[0110] Example 5 Effect of Pediococcus acidilactici on egg quality

[0111] 1. Materials and Methods

[0112] In this example, 960 352-day-old Hy-Line brown laying hens were randomly divided into three groups: the first group was a blank control group (CON, fed with a basic diet), the second group was a low-dose Pediococcus acidilactici group (LPa, basic diet + 1×10 8 CFU / kg diet), the third group was a high-dose Pediococcus acidilactici group (HPa, basic diet + 1×10 9 CFU / kg diet), 4 replicates per group, 80 chickens per replicate. The duration was 6 weeks (1 week for pre-test and 5 weeks for formal period).

[0113] At the end of the experiment, 150 eggs were randomly selected from each group for egg quality measurement, including eggshell strength, eggshell thickness, albumen height, yolk color, and Haugh units.

[0114] 2. Results

[0115] Adding lactic acid bacteria to feed had no significant effect on eggshell thickness, but it could improve eggshell strength. Adding low-dose lactic acid bacteria significantly increased eggshell strength (16%, P <0.05), but high doses of Pediococcus acidilactici had no significant effect on improving eggshell strength, while adding Pediococcus acidilactici could significantly improve egg yolk color. The above results show that adding Pediococcus acidilactici to feed can significantly improve egg quality (Table 4).

[0116] Table 4 Effects of Pediococcus acidilactici on egg quality

[0117] Note: Data in the same industry with different letters on their shoulders indicate significant differences. P <0.05).

[0118] Example 6 Application of Pediococcus acidilactici in improving the antioxidant capacity of laying hens

[0119] In this example, 960 352-day-old Hy-Line brown laying hens were randomly divided into three groups: the first group was a blank control group (CON, fed with a basic diet), the second group was a low-dose Pediococcus acidilactici group (LPa, basic diet + 1×10 8 CFU / kg diet), the third group was a high-dose Pediococcus acidilactici group (HPa, basic diet + 1×10 9 CFU / kg diet), 4 replicates per group, 80 chickens per replicate. The duration was 6 weeks (1 week for pre-test and 5 weeks for formal period).

[0120] On the day when the experiment ended, blood was collected from the wing vein of two laying hens in each replicate, placed in a blood collection tube, centrifuged, and plasma was collected for the determination of antioxidant indicators. Plasma antioxidant indicators include: glutathione peroxidase (GSH-Px), superoxide dismutase (SOD), catalase (CAT), malondialdehyde (MDA) concentration, and total antioxidant capacity (T-AOC).

[0121] 2. Results

[0122] Both low-dose and high-dose addition of Pediococcus acidilactici to feed significantly increased the total antioxidant capacity (T-AOC) and glutathione peroxidase (GSH-Px) activity of plasma ( P <0.05), significantly reduced the content of MDA ( P <0.05). The above results showed that both high-dose and low-dose Pediococcus acidilactici could significantly improve the antioxidant capacity of laying hen plasma (Table 5).

[0123] Table 5 Effects of Pediococcus acidilactici on the antioxidant capacity of laying hen plasma

[0124] Example 7 Application of Pediococcus acidilactici in reducing cholesterol in eggs

[0125] 1. Materials and Methods

[0126] In this example, 960 352-day-old Hy-Line brown laying hens were randomly divided into three groups: the first group was a blank control group (CON, fed with a basic diet), the second group was a low-dose Pediococcus acidilactici group (LPa, basic diet + 1×10 8 CFU / kg diet), the third group was a high-dose Pediococcus acidilactici group (HPa, basic diet + 1×10 9 CFU / kg diet), 4 replicates per group, 80 chickens per replicate. The duration was 6 weeks (1 week for pre-test and 5 weeks for formal period).

[0127] On the day when the experiment ended, blood was collected from the wing veins of two laying hens randomly selected for each replicate, placed in blood collection tubes, centrifuged, and plasma was collected for the detection of total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C). At the end of the experiment, 150 eggs were randomly selected from each group for the determination of egg cholesterol content.

[0128] 2. Results

[0129] Adding Pediococcus acidilactici to feed can significantly reduce the TC content in laying hens' plasma ( P <0.05); low dose of lactic acid Pediococcus can significantly reduce plasma TG, and high dose can also reduce TG ( P<0.05), but the effect was slightly lower than that of the low dose (Table 6).

[0130] Table 6 Effects of Pediococcus acidilactici on plasma biochemical parameters of laying hens

[0131] Further measurement of the cholesterol content in eggs revealed that the cholesterol content in each egg decreased from 242 mg to 188 mg after feeding with Pediococcus acidilactici, a decrease of 22% ( Fig.16 ). The above results indicate that Pediococcus acidilactici can reduce the cholesterol level in laying hens, thereby reducing the cholesterol level deposited in eggs.

[0132] Example 8 Preparation method of Pediococcus acidilactici preparation

[0133] The preparation method of the Pediococcus acidilactici preparation provided in this embodiment comprises the following steps: (1) Inoculate Pediococcus acidilactici A62 into MRS medium, place it in a constant temperature incubator at 37°C for 12 hours, then inoculate it into the fermentation medium of a fermenter at an inoculum rate of 5% to 10% (volume ratio), and culture it for 18 to 24 hours to obtain a fermentation liquid (liquid preparation) of Pediococcus acidilactici; The fermentation medium is: molasses 5%, soybean meal 2%, ammonium sulfate 0.1%, crystalline sodium acetate 0.1%, dipotassium hydrogen phosphate 0.5%, anhydrous magnesium sulfate 0.02%, manganese sulfate 0.005%, Tween-80 0.1% v / v, pH 6.5 ± 0.2; (2) The lactic acid Pediococcus fermentation liquid and the carrier are mixed evenly in a weight ratio of (0.5-0.8):1, dried at 40-50°C, and crushed to obtain the product.

[0134] Although the present invention has been described in detail above with general descriptions and specific embodiments, it is obvious to those skilled in the art that some modifications or improvements can be made based on the present invention. Therefore, these modifications or improvements made without departing from the spirit of the present invention all fall within the scope of protection claimed by the present invention.

Claims

1. A Pediococcus acidilactici preparation, characterized in that: The lactic acid Pediococcus preparation is a lactic acid Pediococcus ( Pediococcus acidilactici ) The fermentation liquid of A62 and the carrier are mixed in a weight ratio of (0.5-0.8):1, dried at low temperature, and crushed to obtain a dry powder of Pediococcus acidilactici; The deposit number of the Pediococcus acidilactici A62 is CGMCC NO. 28922; The carrier is selected from one or more of bran, rice husk powder, rice flour, corn cob powder and corn gluten powder.

2. The method for preparing the Pediococcus acidilactici preparation according to claim 1, characterized in that: The following steps are involved: (1) inoculating the lactic acid Pediococcus into an MRS culture medium, placing the culture medium in a constant temperature incubator at 37° C. for 12 h, and then inoculating the culture medium into a fermentation tank at an inoculation rate of 5% to 10%, culturing the culture medium for 18 to 24 h, and obtaining a fermentation liquid of the lactic acid Pediococcus; The fermentation medium is: molasses 5%, soybean meal 2%, ammonium sulfate 0.1%, crystalline sodium acetate 0.1%, dipotassium hydrogen phosphate 0.5%, anhydrous magnesium sulfate 0.02%, manganese sulfate 0.005%, Tween-80 0.1% v / v, pH 6.5 ± 0.2; (2) The fermentation liquid of Pediococcus acidilactici and the carrier are mixed evenly in a weight ratio of (0.5-0.8):1, dried at 40-50°C, and crushed to obtain the product.

3. Use of Pediococcus acidilactici A62 or its bacterial agent or the Pediococcus acidilactici preparation according to claim 1 in the preparation of a medicament for reducing the weight of obese animals and obese people and lowering serum cholesterol.

4. The use according to claim 3, characterized in that: The animals include mice and livestock and poultry.

5. Use of Pediococcus acidilactici A62 or its bacterial agent or the Pediococcus acidilactici preparation according to claim 1 in improving the antioxidant capacity and immune function of mice.

6. Use of Pediococcus acidilactici A62 or its bacterial agent or the Pediococcus acidilactici preparation according to claim 1 in improving the intestinal flora of mice.

7. Use of Pediococcus acidilactici A62 or its bacterial agent or the Pediococcus acidilactici preparation according to claim 1 in improving the production performance of livestock and poultry.

8. Use of Pediococcus acidilactici A62 or its bacterial agent or the Pediococcus acidilactici preparation according to claim 1 in improving the antioxidant capacity of livestock and poultry.

9. Use of Pediococcus acidilactici A62 or its bacterial agent or the Pediococcus acidilactici preparation according to claim 1 in improving the quality of poultry eggs.

10. The use according to claim 9, characterized in that: The improving egg quality comprises reducing egg cholesterol.